Germany · Delayed Price · Currency is EUR Everest Medicines Statistics
Total Valuation
FRA:6HN has a market cap or net worth of EUR 1.82 billion. The enterprise value is 1.72 billion.
| Market Cap | 1.82B |
| Enterprise Value | 1.72B |
Important Dates
The last earnings date was Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 353.26M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.07% |
| Owned by Institutions (%) | 11.76% |
| Float | 264.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.02 |
| PB Ratio | 3.91 |
| P/TBV Ratio | 9.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -21.97 |
| EV / Sales | 16.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -29.67 |
Financial Position
The company has a current ratio of 5.46, with a Debt / Equity ratio of 0.19.
| Current Ratio | 5.46 |
| Quick Ratio | 5.36 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.51 |
| Interest Coverage | -31.72 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -15.87% |
| Revenue Per Employee | 140,145 |
| Profits Per Employee | -108,449 |
| Employee Count | 665 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +28.17% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +28.17% |
| 50-Day Moving Average | 5.45 |
| 200-Day Moving Average | 6.07 |
| Relative Strength Index (RSI) | 46.14 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:6HN had revenue of EUR 101.18 million and -78.30 million in losses. Loss per share was -0.24.
| Revenue | 101.18M |
| Gross Profit | 70.98M |
| Operating Income | -86.31M |
| Pretax Income | -78.30M |
| Net Income | -78.30M |
| EBITDA | -70.68M |
| EBIT | -86.31M |
| Loss Per Share | -0.24 |
Balance Sheet
The company has 188.50 million in cash and 87.36 million in debt, giving a net cash position of 101.14 million.
| Cash & Cash Equivalents | 188.50M |
| Total Debt | 87.36M |
| Net Cash | 101.14M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 466.70M |
| Book Value Per Share | 1.43 |
| Working Capital | 189.48M |
Cash Flow
In the last 12 months, operating cash flow was -53.02 million and capital expenditures -4.95 million, giving a free cash flow of -57.97 million.
| Operating Cash Flow | -53.02M |
| Capital Expenditures | -4.95M |
| Free Cash Flow | -57.97M |
| FCF Per Share | n/a |
Margins
Gross margin is 70.15%, with operating and profit margins of -85.30% and -77.38%.
| Gross Margin | 70.15% |
| Operating Margin | -85.30% |
| Pretax Margin | -77.38% |
| Profit Margin | -77.38% |
| EBITDA Margin | -69.86% |
| EBIT Margin | -85.30% |
| FCF Margin | n/a |
Dividends & Yields
FRA:6HN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.25% |
| Shareholder Yield | -0.25% |
| Earnings Yield | -4.30% |
| FCF Yield | -3.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:6HN has an Altman Z-Score of 3.97 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.97 |
| Piotroski F-Score | 2 |